Pamela Stephenson, M.P.H.

Pamela Stephenson, M.P.H.

Chief Commercial OfficeratDisc Medicine· In proxies 2024–2025

Pay in FY2025-20% from the year before · Disc Medicine stock +25.3% the same year

Pamela Stephenson, M.P.H. was paid $4.2M in FY2025 (Dec), down 20%. Disc Medicine stock rose 25.3% that year.

Pay$100 in the stock at the end of FY23 → $137
Pay is from the Summary Compensation Table of each Disc Medicine proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Disc MedicinePublic company · 2 yr
    • Chief Commercial Officer2024 – Present · 2 yrStock in role +36%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?